Skip to main content

Table 4 Comparison between patients with and without nephrolithiasis (clinical characteristics)

From: Nephrolithiasis in gout: prevalence and characteristics of Brazilian patients

 

Nephrolithiasis (N = 43)

Without Nephrolithiasis (N = 80)

P Value

Male gender

43 (100%)

72 (90.0%)

0.049

Skin color/race: white

37 (86.0%)

65 (81.2%)

0.500

Age (years)

61.3 ± 9.7

63.8 ± 9.3

0.161

Age of onset of disease (years)

42.3 ± 11.4

46.4 ± 12.7

0.080

Duration of disease (years)

19.0 ± 10.8

17.8 ± 10.4

0.502

 < 5 years

1 (9.1%)*

10 (90.9%)*

0.168†

 5–15 years

19 (38.0%)*

31 (62.0%)*

 > 15 years

23 (37.1%)*

39 (62.9%)*

Tophi

24 (55.8%)

45 (56.2%)

0.963

Underexcretion of uric acid

38 (88.4%)

72 (91.4%)

0.624

Alcohol use disorder

36 (83.7%)

54 (67.5%)

0.053

 Current

9 (20.9%)

14 (17.5%)

0.642

 Past

27 (62.8%)

40 (50.0%)

0.174

Smoking history

25 (58.1%)

38 (47.5%)

0.260

 Current

2 (4.7%)

8 (10.0%)

0.491

 Past

23 (53.5%)

30 (37.5%)

0.088

Medication

 Allopurinol

19 (44.2%)

26 (32.5%)

0.199

 Benzbromarone

21 (48.8%)

55 (68.8%)

0.030

 Potassium citrate

13 (30.2%)

Zero

< 0.001

 Colchicine

15 (34.9%)

17 (21.2%)

0.100

 Glucocorticoids

2 (4.7%)

5 (6.2%)

1.000

 NSAIDs

23 (53.5%)

41 (51.2%)

0.813

 Antidiabetic medication

10 (23.3%)

8 (10.0%)

0.047

 Antihypertensives

34 (79.1%)

58 (72.5%)

0.424

 Lipid-lowering medication

15 (34.9%)

10 (12.5%)

0.003

  1. Data are expressed as the total (%) or the mean ± SD, unless otherwise stated
  2. NSAIDs nonsteroidal anti-inflammatory drugs
  3. * Percentage for each subgroup
  4. p value for the comparison among the three disease duration subgroups